Optimizing precision lung cancer screening using willingness-to-pay–anchored risk eligibility thresholds
Abstract
Background: Despite the proven benefits of low-dose computed tomography (LDCT) in lung cancer management, uptake remains limited due to cost. This study applies a structured decision-analytic framework to optimize LDCT screening through risk-based strategies in Singapore compared with conventional LDCT (based on age and smoking history) and no screening.
Methods: We developed a lifetime Markov model to simulate costs and outcomes for Singaporean smokers and never-smokers with a family history of lung cancer, stratified by sex. Transition probabilities and costs were informed by local data, with utilities from published sources. Screening strategies varied by start age (50, 55, 60) and frequency (annual, biennial, triennial). Outcomes included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 3% annually. Using a validated local risk prediction model, reverse threshold analyses identified optimal risk cut-offs for cost-effective screening, supported by deterministic and probabilistic sensitivity analyses across willingness-to-pay thresholds of Singapore dollars (SGD) 45,000–75,000/QALY.
Results: Among smokers, annual risk-based screening from age 50 at 1-year risk thresholds of ≥ 0.37% for males and ≥ 0.51% for females produced the greatest health gains (ΔQALYs vs. no screening: 0.201 and 0.198, respectively), while the same risk-based annual screening from age 60 was most economically efficient (ΔQALYs: 0.177 and 0.182; incremental ICERs: SGD 40,155/QALY and SGD 42,666/QALY, respectively). Among never-smokers with a family history of lung cancer, conventional LDCT was not cost-effective; annual risk-based screening from age 50 in males at 1-year risk threshold of ≥ 0.16% and females at ≥ 0.21% maximized health gains (ΔQALYs: 0.013 and 0.021, respectively), while less intensive screening from age 60–biennial in males at 1-year risk ≥ 0.20% and triennial in females at ≥ 0.21%–was more economically efficient (ΔQALYs: 0.007 and 0.011; incremental ICERs: SGD 73,548/QALY and SGD 26,953/QALY, respectively).
Conclusions: Risk-based LDCT screening may improve screening efficiency and health gains while maintaining good value for money, with different screening intensities offering implementation options under varying budget constraints, though further research is needed to support its implementation in practice. These findings provide evidence to inform risk-based screening eligibility and implementation strategies, particularly in Asia with a high burden of lung cancer among never-smokers.
Related
- Expanded American Cancer Society Lung Cancer Screening Eligibility and Predicted Risk
- Development and Pilot Assessment of an AI-Generated Digital Donor Eligibility Screening Tool in Saudi Blood Banks: A Quality Improvement Study
- Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models
- Effect of eligibility for referral following mass screening for severe acute malnutrition using mid-upper arm circumference: A prospective regression discontinuity design
- Mapping Preeclampsia Risk Thresholds to Screen-Positive Rates in Routine First-Trimester Screening: A Single-Centre Audit
BibTeX
@article{juang2026optimizing,
title = {{Optimizing precision lung cancer screening using willingness-to-pay–anchored risk eligibility thresholds}},
author = {Yah Ru Juang and Yue Zhang and Anthony Chau Ang Yii and Borame L Dickens and Yichen He and Shihui Jin and Laura Huey Mien Lim and Wei Jie Seow and Wenjia Chen},
journal = {BMC Medicine},
year = {2026},
month = oct,
doi = {10.1186/s12916-026-05360-3},
url = {https://link.springer.com/article/10.1186/s12916-026-05360-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Optimizing precision lung cancer screening using willingness-to-pay–anchored risk eligibility thresholds
AU - Yah Ru Juang
AU - Yue Zhang
AU - Anthony Chau Ang Yii
AU - Borame L Dickens
AU - Yichen He
AU - Shihui Jin
AU - Laura Huey Mien Lim
AU - Wei Jie Seow
AU - Wenjia Chen
PY - 2026
DA - 2026/10/27
JO - BMC Medicine
DO - 10.1186/s12916-026-05360-3
UR - https://link.springer.com/article/10.1186/s12916-026-05360-3
AB - Background: Despite the proven benefits of low-dose computed tomography (LDCT) in lung cancer management, uptake remains limited due to cost. This study applies a structured decision-analytic framework to optimize LDCT screening through risk-based strategies in Singapore compared with conventional LDCT (based on age and smoking history) and no screening. Methods: We developed a lifetime Markov model to simulate costs and outcomes for Singaporean smokers and never-smokers with a family history of lung cancer, stratified by sex. Transition probabilities and costs were informed by local data, with utilities from published sources. Screening strategies varied by start age (50, 55, 60) and frequency (annual, biennial, triennial). Outcomes included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), discounted at 3% annually. Using a validated local risk prediction model, reverse threshold analyses identified optimal risk cut-offs for cost-effective screening, supported by deterministic and probabilistic sensitivity analyses across willingness-to-pay thresholds of Singapore dollars (SGD) 45,000–75,000/QALY. Results: Among smokers, annual risk-based screening from age 50 at 1-year risk thresholds of ≥ 0.37% for males and ≥ 0.51% for females produced the greatest health gains (ΔQALYs vs. no screening: 0.201 and 0.198, respectively), while the same risk-based annual screening from age 60 was most economically efficient (ΔQALYs: 0.177 and 0.182; incremental ICERs: SGD 40,155/QALY and SGD 42,666/QALY, respectively). Among never-smokers with a family history of lung cancer, conventional LDCT was not cost-effective; annual risk-based screening from age 50 in males at 1-year risk threshold of ≥ 0.16% and females at ≥ 0.21% maximized health gains (ΔQALYs: 0.013 and 0.021, respectively), while less intensive screening from age 60–biennial in males at 1-year risk ≥ 0.20% and triennial in females at ≥ 0.21%–was more economically efficient (ΔQALYs: 0.007 and 0.011; incremental ICERs: SGD 73,548/QALY and SGD 26,953/QALY, respectively). Conclusions: Risk-based LDCT screening may improve screening efficiency and health gains while maintaining good value for money, with different screening intensities offering implementation options under varying budget constraints, though further research is needed to support its implementation in practice. These findings provide evidence to inform risk-based screening eligibility and implementation strategies, particularly in Asia with a high burden of lung cancer among never-smokers.
SN - 1741-7015
ER -